1 min read
Add as a preferred source on GooglePAVmed Advances Veris Implantable Monitor Toward Early 2027 FDA Filing
Veris Health’s monitor reached design freeze, and a 90-day GLP animal study began in October.
PAVmed Inc. is advancing Veris Health Inc.’s implantable physiological monitor toward an early 2027 submission to the U.S. Food and Drug Administration (FDA) through the 510(k) pathway. The device reached design freeze, and a 90-day GLP animal study began in October.
The FDA submission remains targeted for early 2027.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.